Abstract
Lyme disease is the most common vector-borne infection in the United States. Recent dramatic increases in the number of reported cases reflect increased disease awareness, as well as spread of infected vectors and reservoirs into most geographic regions in the US. Currently, the only practical laboratory means of diagnosing Lyme disease is based on serologic tests. The demand for these tests has soared as more physicians and the lay public confront the protean clinical manifestations of Borrelia burgdorferi infection. Enzyme-linked immunosorbent analysis (ELISA) is the most useful serologic method currently available; nonetheless, this and other methods are hampered by false–positive and false–negative results. This article reviews the human immune response to B. burgdorferi, the various available Lyme disease serodiagnostic tests, the causes of false serologic test results, and prospects for improvements in Lyme disease diagnosis.
